GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Talphera Inc (NAS:TLPH) » Definitions » YoY Rev. per Sh. Growth

TLPH (Talphera) YoY Rev. per Sh. Growth : -100.00% (As of Dec. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Talphera YoY Rev. per Sh. Growth?

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. Talphera's YoY Rev. per Sh. Growth for the quarter that ended in Dec. 2024 was -100.00%.

Talphera's Revenue per Share for the three months ended in Dec. 2024 was $0.00.

Talphera YoY Rev. per Sh. Growth Historical Data

The historical data trend for Talphera's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Talphera YoY Rev. per Sh. Growth Chart

Talphera Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
YoY Rev. per Sh. Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 119.72 -62.99 -100.00 - -100.00

Talphera Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
YoY Rev. per Sh. Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -100.00 -100.00 -100.00

Talphera YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

Talphera's YoY Rev. per Sh. Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY Rev. per Sh. Growth (A: Dec. 2024 )
=(Revenue per Share (A: Dec. 2024 )-Revenue per Share (A: Dec. 2023 ))/ | Revenue per Share (A: Dec. 2023 ) |
=(0-0.046)/ | 0.046 |
=-100.00 %

Talphera's YoY Rev. per Sh. Growth for the quarter that ended in Dec. 2024 is calculated as:

YoY Rev. per Sh. Growth (Q: Dec. 2024 )
=(Revenue per Share (Q: Dec. 2024 )-Revenue per Share (Q: Dec. 2023 )) / | Revenue per Share (Q: Dec. 2023 )) |
=(0-0.015)/ | 0.015 |
=-100.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Talphera YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of Talphera's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Talphera Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Talphera Inc (NAS:TLPH) » Definitions » YoY Rev. per Sh. Growth
Comparable Companies
MSTH HYEX FLGC LVRLF BIOE BFRI AYTU SNOA TXMD CBIH ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD NSE:DIVISLAB HKSE:03692 XSWX:SDZ XTAE:TEVA
Traded in Other Exchanges
R5XA:Germany R5XA:Germany
Address
1850 Gateway Drive, Suite 175, San Mateo, CA, USA, 94404
Website
https://www.talphera.com
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
Executives
Vincent J. Angotti director, officer: Chief Executive Officer C/O ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Raffi Asadorian officer: Chief Financial Officer C/O ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Pamela P Palmer director, officer: Chief Medical Officer C/O ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Jill Marie Broadfoot director 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Marina Bozilenko director C/O ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Adrian Adams director C/O AUXILIUM PHARMACEUTICALS, INC., 640 LEE ROAD, CHESTERBROOK PA 19355
Mark G Edwards director ALLOS THERAPEUTICS, INC., 11080 CIRCLEPOINT ROAD, SUITE 200, WESTMINSTER CO 80020
Badri N Dasu officer: Chief Engineering Officer C/O ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Lawrence G Hamel officer: Chief Development Officer C/O ACELRX PHARMACEUTICALS INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Mark A Wan director, 10 percent owner C/O THREE ARCH PARTNERS, 3200 ALPINE RD, PORTOLA VALLEY CA 94028
Three Arch Associates Iii Lp 10 percent owner C/O THREE ARCH PARTNERS, 3200 ALPINE ROAD, PORTOLA VALLEY CA 94028
Wilfred E Jaeger 10 percent owner C/O THREE ARCH PARTNERS, 3200 ALPINE RD, PORTOLA VALLEY CA 94028
Three Arch Partners Iii Lp 10 percent owner
Three Arch Partners Iv Lp 10 percent owner
Three Arch Associates Iv Lp 10 percent owner 3200 ALPINE ROAD, PORTOLA VALLEY CA 94028